The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes one thing I can never understand is that there investors chasing other biotechs with drug discovery at much earlier stages and yet this is languishing with an approved drug in various markets and major approvals for launching new drugs coming soon.
I suppose the other shares attract a lot of traders for their 10-20% but this one is seen as boring? A lot of traders lose money in the long term so that game is only for very skilled traders. It's more stressful as well watching shares all day!
Anyway happy to hold here on a long term view - once the 2 forthcoming approvals are in it will be very safe holding here and the upside from here is huge.
The Chief Executive I recall in one of the recent shareholder presentation talks mentioned that the board have experience of exiting investments. With a strong pipeline it might get gobbled up in a year or two?
DNL = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping iant here .GL
Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021
Let's see this head to the 40s now
GREAT NEWS OUT
Market cap £25 million
Chronocort MAA Submitted in Europe
[url]https://www.investegate.co.uk/diurnal-group-plc--dnl-/rns/chronocort-maa-submitted-in-europe/201912160700079030W/[/url]
Significant opportunity to address unmet patient need, in a market estimated at $250 million
Marketing authorisation anticipated in Q1 2021
Yes a big market to tap into.
Patients would much prefer a tablet/capsule then the current gel(s) that is available.
Two big pieces of news due in the next 6 weeks or so too.
This will then be at a much higher level
DNL still the cheapest and most attractive biotech in GB .I screnned all GB Biotech and there is no better smallcap than this .
****************************/articles/diurnal-group-surges-on-successful-testosterone-clinical-study-95dd288/
He added: “We look forward to engaging with regulators in the US and Europe to progress DITEST™ to late stage clinical trials, and to discussing these positive trial data with potential development and commercialisation partners ."
Diurnal believes the product could be the first effective oral native testosterone treatment in what it estimates to be a $4.8 billion global market.
Another little top up. showing as a sell.
This is off the radar atm but when the potential here becomes more widely known it should show a very healthy return. Just a bit of patience required.
Great news out today and much more to come ...
Diurnal (DNL) Price:30p --Market Cap £26 M --Cash £9 M--MEGA milestones expected within 4 weeks = 300-500% GEM
Approaching anumber of near-term milestones....5 November 2019
https://www.hardmanandco.com/wp-content/uploads/2019/11/DNL-2019-results-5-November-2019.pdf
Valuation -DCF 202p per share
The consequence of the Chronocort trial outcome is minimal in the bigger picture, as it has delayed both the EMA MAA submission and the start of the US Phase III trial only by about six months. Hence, there has not been a material change to our DCF valuation based on our clearly-stated assumptions in ourresearch note, published on 25 April 2019. The net present value of the cashflows that could be generated from DNL’s first two products equates to £305m. Risk-adjustment to take account of the different stages of development in different territories reduces this to £171m, or 202p per share.
DITEST™(Hypogonadism) study readout Q4 2019
Alkindi® US NDA submission to the FDA(paediatric AI,including CAH)Q4 2019
Chronocort® European regulatory submission to the EMA(CAH)Q4 2019
Conclude US partnering discussions for Alkindi®(Chronocort®)H1 2020
Presentation
https://www.diurnal.co.uk/media/36783/full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf
small consolidation ongoing after the nice jump , any dip here is a gift here with lots of big news on the way . DNL is still the most attractive and underpriced UK-Biotech .GL
going up step by step and company is still heavily undervalued at market cap of 39 million and the best is still to come during 2H 2019 .STRONG BUY
Shareholders here should put high gtc sell order in like 100p ,so your shares willnot available for shorts and more important it reduces the free shares on market so it helps the stock to make even much bigger jumpf on good news . Thank you guys
How to Prevent your Shares Holdings from being Shorted
Q:What can you do to prevent your shares holdings from being shorted?
A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account.
There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are ‘on order’ they cannot be lent out by your broker and in turn you are reducing the amount of ‘free shares’ out there that can be used for shorting purposes. And don’t forget to move your limit order up when the price starts to recover, then, that way your shares can’t be shorted – not much but helps :D.
Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on.
In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.
Kaaaaaaaaaaaabooooooom and its still a gift at 34 million valuation .enjoy the ride ,like i said before i think that 100p+ before year end is very likely especially on big news like partner deals wich could happen anytime now and the NDA/EMA submission for approval next quarter . HOTTEST PICK in the pharma sector .GL
Please put your shares on a sell limit of 100p or a little bit more, It can lead to more big and fast price jumps. It doesn't cost anything! Let's try it! It has shown positive in the past. Gooo, Gooooo.. See you next at 60p ;)
the downside is very very very limited , DNL is well financed after cap raising a few weeks ago and more cash will come through new Partnerships for the large markets like USA which expected anytime now . Market cap of 32 million is still a pure gift for this company . DNL can go easily above 100p and it would be still cheap .GLTA
Upcoming Milestones
Alkindi launch in additional EU States during 2H 2019
US-NDA submission for Alkindi in Q4 2019
EMA submission for Chronocort approval in Q4 2019
US-Partner Deal for Alkindi could happen anytime now
US-Partner Deal for Chronocort could happen anytime now
Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now
“Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI. The US remains an important market for Diurnal’s late-stage pipeline focused on cortisol deficiency, with a combined market size for the treatment of CAH and paediatric AI estimated at $132m, and a future expansion opportunity in adult AI, which represents a $0.9bn market opportunity in the US.”
It could, but I’m not sure why any holders would sell at this point - the upside is clear and news could drop at any time...
Look at Shield Therapeutics -STX- I think we’ll follow a similar path over the rest of this year
Could quite easily go the opposite direction though.
major breakout imminent which could push stock to 60-70p quickly
DNL is a MEGA opportunity at current valuation of only 31 Million any good news could change that very quickly and there are lot of news coming within next 4 months even buyout is possible here .GLTA
Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Riskadjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share.
“Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI. The US remains an important market for Diurnal’s late-stage pipeline focused on cortisol deficiency, with a combined market size for the treatment of CAH and paediatric AI estimated at $132m, and a future expansion opportunity in adult AI, which represents a $0.9bn market opportunity in the US.”
Spiderman,
to answer your question, one of the drugs, Alkindi, failed to get a licence or something. This was due to the way the data was presented (according to the CEO last month) and it is expected to get approval in the next 12 months.
Search youtube for diurnal and you can watch the presentation (I was there, the CEO was very genuine through this presentation and after when I spoke to him). I invested as a result and I am very pleased so far.
Just realized that UT was done on the 19th :)
That was some UT today 1.5mil!
up 14%+ what a nice day and thats not even the beginning ...A real potential 10 bagger here
Big News like US- Partner deal(s) for Chronocort and Alkindi or Alkindi launch in additional Eu countries could happen anytime now which could push this low float stock back above 100p quickly . Market cap of 29 million is a pure gift for this company .GLTA
hi spiderman ,looks like you have a good friend and im sure you will be very happy with this dirt cheap stock .And regarding the drop of the sp look at my post below from Fri 15:53 there is your answer .GLTA
Hey guys, I'm new to this site and have recently bought shares on the recommendation of a friend. Can anybody tell me why the SHARE PRICE fell so dramatically a few months ago ??